Try our Advanced Search for more refined results
Al Haj et al v. Pfizer Inc
Case Number:
1:17-cv-06730
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
February 04, 2019
Pfizer Should Face Label Suit, Robitussin Buyers Say
Pharmaceutical giant Pfizer should have to face claims that it's deceitful about the "maximum strength" of its cough medicine Robitussin, a proposed class of consumers told an Illinois federal judge on Friday.
-
January 14, 2019
Robitussin Buyer Seeks Cert. In Label Suit Against Pfizer
A consumer who claims Pfizer Inc. was deceitful about the "maximum strength" of its cough medicine Robitussin has asked an Illinois federal judge to certify a nationwide class of buyers who allegedly paid more for a weaker product.
-
August 03, 2018
High Court Ruling Can't Help Pfizer 'Win The Day' In Class Suit
An Illinois federal judge on Friday rejected Pfizer Inc.'s bid to dodge nationwide claims in a lawsuit alleging it overcharges for its "Maximum Strength" Robitussin, saying the U.S. Supreme Court's Bristol-Myers Squibb Co. v. Superior Court of California ruling can't "win the day" for the company.
-
May 22, 2018
Ill. Robitussin Buyers Slam Bid To Toss Nationwide Claims
Consumers blasted Pfizer Inc.'s second bid to toss nationwide class claims from an Illinois federal suit accusing the company of overcharging for its "Maximum Strength" Robitussin, saying Tuesday that its request is not based on new or intervening law.
-
April 25, 2018
Pfizer Slams Out-Of-State Claims Over Robitussin Label
Pfizer Inc. renewed its bid to dismiss nationwide class claims from a suit alleging it overcharged consumers for its "Maximum Strength" Robitussin compared to its regular version, telling an Illinois federal judge on Tuesday the court lacks jurisdiction over out-of-state class members.
-
April 13, 2018
Pfizer Can't Shake Suit Over Deceptive Robitussin Labels
An Illinois federal judge Friday refused to toss nationwide class claims from a suit alleging Pfizer Inc. overcharged consumers for its "Maximum Strength" Robitussin compared to its regular version, finding that the label could be plausibly considered deceptive based on the drugs' relative ingredient mixes.